Want to see QDEL full AI Analyst Report?
QDEL Stock Chart & Stats
$15.05
$0.78(4.86%)
At close: 4:00 PM EDT
$15.05
$0.78(4.86%)
Day’s Range― - ―
52-Week Range$9.92 - $35.58
Previous Close$16.9
Volume1.06M
Average Volume (3M)1.55M
Market Cap
$760.50M
Enterprise Value$3.89K
Total Cash (Recent Filing)$123.40M
Total Debt (Recent Filing)$3.08B
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 04, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.44
Shares Outstanding68,575,424
10 Day Avg. Volume1,339,655
30 Day Avg. Volume1,548,003
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.03
Price to Sales (P/S)0.73
P/FCF Ratio-23.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside-0.33% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)0.77
Revenue Forecast (FY)$2.54B
Bulls Say, Bears Say
Bulls Say
Resilient Ex-China DemandGrowth across major franchises outside China indicates that QuidelOrtho retains meaningful underlying demand and geographic diversification. Strength in laboratories, immunohematology, and point-of-care testing can support durable revenue expansion while reducing dependence on any single market.
Improving Adjusted ProfitabilityStrong adjusted EBITDA growth and margin expansion suggest operating discipline and improving earnings conversion despite a seasonally weak quarter. If sustained, better cost absorption and productivity can strengthen the company’s ability to reinvest and improve cash generation.
Recurring Consumables ModelConsumable sales tied to installed diagnostic instruments create repeat purchasing requirements as customers process patient samples. This model can provide recurring demand, deepen customer relationships, and make the installed base a durable foundation for future revenue.
Bears Say
Deep Profitability DeteriorationSeverely negative profitability indicates that gross profit is currently insufficient to cover the company’s operating and other costs. Persistent losses can erode equity, limit internally funded investment, and require substantial execution improvement before earnings become durable.
Negative Cash GenerationCash consumption weakens financial flexibility and makes growth more dependent on balance-sheet resources or external funding. Management’s withdrawal of full-year free-cash-flow guidance further signals that working-capital and demand uncertainties may continue to pressure cash conversion.
China Regulatory And Leverage PressureRegulatory pricing uncertainty is reducing customer purchases in China, while elevated leverage increases the importance of restoring cash flow and earnings. Together, these pressures can constrain capital allocation and leave less flexibility to absorb continued regional weakness.
QuidelOrtho News
QDEL FAQ
What was QuidelOrtho’s price range in the past 12 months?
QuidelOrtho lowest stock price was $9.92 and its highest was $35.58 in the past 12 months.
What is QuidelOrtho’s market cap?
QuidelOrtho’s market cap is $760.50M.
When is QuidelOrtho’s upcoming earnings report date?
QuidelOrtho’s upcoming earnings report date is Nov 04, 2026 which is in 46 days.
How were QuidelOrtho’s earnings last quarter?
QuidelOrtho released its earnings results on Aug 06, 2026. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of -$0.049 by $0.179.
Is QuidelOrtho overvalued?
According to Wall Street analysts QuidelOrtho’s price is currently Overvalued.
Does QuidelOrtho pay dividends?
QuidelOrtho does not currently pay dividends.
What is QuidelOrtho’s EPS estimate?
QuidelOrtho’s EPS estimate is 0.2.
How many shares outstanding does QuidelOrtho have?
QuidelOrtho has 68,575,424 shares outstanding.
What happened to QuidelOrtho’s price movement after its last earnings report?
QuidelOrtho reported an EPS of $0.13 in its last earnings report, beating expectations of -$0.049. Following the earnings report the stock price went down -24.724%.
Which hedge fund is a major shareholder of QuidelOrtho?
Currently, no hedge funds are holding shares in QDEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$15.00 (-0.33% Downside)
$15.00 (-0.33% Downside)
Blogger Sentiment
Neutral
QDEL Sentiment 60%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 439.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.5%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
QuidelOrtho
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QDEL Company Deck
QDEL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: solid underlying operational performance outside China (mid-single-digit growth ex-China, strong regional results, 21% YoY adjusted EBITDA growth, and margin expansion) and tangible progress on the Lex/Neulixa commercialization. Offsetting these positives were significant near-term headwinds — a 23% revenue decline in China driven by IVD pricing uncertainty, a softer respiratory season, negative operating and free cash flow in the quarter, withdrawal of free-cash-flow guidance, and elevated leverage (4.3x). Management emphasized disciplined cost actions, cash-conversion priorities, and mitigation plans, but the combination of China uncertainty and weak respiratory demand creates meaningful short-term risk even as core franchises remain resilient.View all QDEL earnings summariesQDEL Stock 12 Month Forecast
Average Price Target
$15.00
▼(-0.33% Downside)
Technical Analysis
Ownership Overview
0.89% Insiders
40.99% Mutual Funds
18.47% Other Institutional Investors
5.68% Public Companies and
Individual Investors